C. Hulin

Statistics

Publications

Citations

363

H-Index

Active since

2002

Affiliations

Centre Hospitalier Régional et Universitaire de Nancy(Current)

Inserm

Intergroupe Francophone du Myélome

Hôpital Saint-Antoine

Centre Hospitalier Universitaire de Nantes

C. Hulin is an author at Centre Hospitalier Régional et Universitaire de Nancy specializing in medicine, multiple myeloma, and multiple myeloma therapy.

Publications per year

2002–2014

Publications

Minor clone provides a reservoir for relapse in multiple myeloma

Florence Magrangeas, Hervé Avet‐Loiseau, Wilfried Gouraud et al. · Leukemia · 2012 · 121 citations

Medicine, Hematology, Oncology +14

Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma.

Thierry Façon, Jean‐Yves Mary, C. Hulin et al. · Blood · 2005 · 65 citations

Medicine, Hematology, Oncology +17

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

Martin Kropff, H Baylon, Tadeusz Robak et al. · Haematologica · 2011 · 55 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

M.-L. Chretien, Benjamin Hébraud, V. Cances-Lauwers et al. · Haematologica · 2014 · 49 citations · Full text

Medicine, Geriatric Medicine, Oncology +16

Randomized Clinical Trial Comparing Melphalan-Prednisone (MP), MP-Thalidomide (MP-THAL) and High-Dose Therapy Using Melphalan 100 MG/M2 (MEL100) for Newly Diagnosed Myeloma Patients Aged 65–75 Years. Interim Analysis of the IFM 99-06 Trial on 350 Patients.

Thierry Façon, Jean Yves Mary, C. Hulin et al. · Blood · 2004 · 26 citations

Medicine, Hematology, Oncology +17

1–5 of 8